[Form 4] CVRx, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brent Binkowski, Chief Operating Officer of CVRx (CVRX), acquired equity awards on 08/11/2025 that increase his direct stake in the company. He received 16,600 restricted stock units that vest 25% on each anniversary of the grant date, and was granted stock options for 74,900 shares with an exercise price of $7.51. The options vest 25% after one year and then 1/48th per month thereafter and have an expiration date listed as 08/10/2035. Following these transactions, the reporting person directly beneficially owns 16,600 shares and holds options for 74,900 shares.

Positive

• Acquisition of 16,600 restricted stock units, increasing direct ownership and aligning the COO with shareholder value
• Grant of 74,900 stock options with a standard multi-year vesting schedule, supporting executive retention and long-term alignment

Negative

• Potential dilution of 74,900 shares from the option grant (combined potential interest of 91,500 shares), though percentage impact is not disclosed
• Vesting delays mean the options and some RSUs are not immediately exercisable, limiting near-term voting or liquidity impact

Insights

Corporate Governance Expert

TL;DR: Routine executive compensation grants that align management with shareholders through multi-year vesting.

The reported awards to the COO are structured as time-based equity compensation: restricted stock units that vest 25% per year and options that vest 25% after one year then monthly thereafter. This structure is consistent with retention and alignment practices, linking pay to continued service. The direct ownership after the grants is 16,600 shares and 74,900 options, both held directly. Without outstanding share counts, the materiality to existing shareholders cannot be quantified, but the grant design is typical for executive retention.

Securities Analyst

TL;DR: Insider acquired 16,600 RSUs and 74,900 options at $7.51; potential dilution equals 91,500 shares but impact needs total share count.

The transaction increases the reporting person's economic exposure by 16,600 shares delivered as restricted stock units and by the right to purchase 74,900 shares at an exercise price of $7.51. Combined, that represents 91,500 shares of current or potential direct interest. The options expire on 08/10/2035 and vest over time, limiting immediate convertibility. Assessing investor impact requires the company's outstanding share count and any previously outstanding in-the-money awards; those figures are not provided in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Binkowski Brent

(Last) (First) (Middle)

9201 WEST BROADWAY AVENUE

SUITE 650

(Street)

MINNEAPOLIS MN 55445

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVRx, Inc. [ CVRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		A		16,600(1)	A	$0	16,600	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.51	08/11/2025		A		74,900		(2)	08/10/2035	Common Stock	74,900	$0	74,900	D

Explanation of Responses:

1. Restricted stock units that vest 25% on each anniversary of the grant date

2. Stock options that vest 25% on the first annual anniversary of the date of grant and then 1/48th per month thereafter.

	/s/ Amy C. Seidel, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Brent Binkowski (CVRX) acquire on 08/11/2025?

He received 16,600 restricted stock units and was granted stock options for 74,900 shares on 08/11/2025.

What is the exercise price and expiration for the CVRX options?

The options have an exercise price of $7.51 and an expiration date listed as 08/10/2035.

How do the RSUs and options vest?

The RSUs vest 25% on each anniversary of the grant. The options vest 25% on the first anniversary then 1/48th per month thereafter.

How many shares does the reporting person beneficially own after the transaction?

Following the reported transactions the reporting person directly owns 16,600 shares and holds options for 74,900 shares.

Does this filing indicate the percentage dilution to CVRX shareholders?

No. The filing lists the number of shares and options but does not provide the company's total outstanding shares, so percentage dilution cannot be calculated from this document.